RNAi specialist Dicerna begins clinical trial; Injectable eye medication launches in U.S.;

> RNAi specialist Dicerna Pharmaceuticals ($DRNA) announced that the first patient has been dosed in the Phase Ib/II clinical trial of its candidate for advanced hepatocellular carcinoma (liver cancer). Release

> pSivida ($PSDV) announced that nationwide shipments of its Iluvien injectable, sustained release micro-insert for the eye condition diabetic macular edema will commence on Feb. 23. The product is licensed to Alimera Sciences. Release

> University of North Carolina spin-off Spyryx Biosciences says it is developing a promising inhaled peptide replacement therapy to help cystic fibrosis patients clear mucus from their lungs. More | More

> The FDA approved the new 0.025 mg/day dosage of the Minivelle estradiol transdermal system for the treatment of postmenopausal osteoporosis. Manufacturer Noven Therapeutics says the medication is the world's smallest estrogen therapy patch. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.